BPC
BIO icon

Bryce Point Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bryce Point Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,597
Closed -$525K – 213
2024
Q4 		$525K Buy
+1,597
New +$542K 0.15% 234

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Veritas Asset Management
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Ariel Investments
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Bryce Point Capital's BIO Position: Q1 2025 in Review

Bryce Point Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 1,597 shares — an estimated $525K sold.

Bryce Point Capital first reported a position in BIO in Q4 2024 and held it in 1 quarter. The position peaked at $525K in Q4 2024. 437 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • Bryce Point Capital reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • Bryce Point Capital sold 1,597 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $525K.
  • Bryce Point Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and held it in 1 quarter.
  • Bryce Point Capital's Bio-Rad Laboratories Class A position peaked at $525K in Q4 2024.
  • 437 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.